New treatments for ulcerative colitis: do we have pediatric data?

References

• Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55(3):340–361.
   PubMed Web of Science ®Google Scholar
• Turner D, Travis SP, Griffiths AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol. 2011;106(4):574–588.
   PubMed Web of Science ®Google Scholar
• Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135(4):1114–1122.
   PubMed Web of Science ®Google Scholar
• Fumery M, Duricova D, Gower-Rousseau C, et al. Review article: the natural history of paediatric-onset ulcerative colitis in population-based studies. Aliment Pharmacol Ther. 2016;43(3):346–355.
   PubMed Web of Science ®Google Scholar
• Feagan BGM, MacDonald JKM. Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18(9):1785–1794.
   PubMed Web of Science ®Google Scholar
• Turner D, Yerushalmi B, Kori M, et al. Once versus twice daily mesalazine to induce remission in pediatric ulcerative colitis: a randomized controlled trial. J Pediatr Gastroenterol Nutr. 2016. Supplement.
   Google Scholar
• Armstrong L, Sharif JA, Galloway P, et al. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine. Aliment Pharmacol Ther. 2011;34(9):1106–1114.
   PubMed Web of Science ®Google Scholar
• Falaiye TO, Mitchell KR, Lu Z, et al. Outcome following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2014;58(2):213–219.
   PubMed Web of Science ®Google Scholar
• Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate-to-severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10(4):391–399.
   PubMed Web of Science ®Google Scholar
• Volonaki E, Mutalib M, Kiparissi F, et al. Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis. Eur J Gastroenterol Hepatol. 2015;27(12):1425–1428.
   PubMed Web of Science ®Google Scholar
• Sieczkowska J, Jarzębicka D, Banaszkiewicz A, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohns Colitis. 2016;10(2):127–132.
   PubMed Web of Science ®Google Scholar
• Turner D, Koletzko S, Griffiths AM, et al. Use of placebo in pediatric inflammatory bowel diseases: a position paper from ESPGHAN, ECCO, PIBDnet, and the Canadian children IBD network. J Pediatr Gastroenterol Nutr. 2016;62(1):183–187.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New Engl J Med. 2013;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Singh N, Patel M, Rabizadeh S, et al. Vedolizumab use in pediatric patients with inflammatory bowel disease. Gastroenterology. 2015;148(4):S–72.
   Google Scholar
• Stein RE, Conrad MA, Maxwell EC, et al. The use of vedolizumab for treatment of severe pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2015;61(Supp 2):S89.
   Google Scholar
• Shealy DJ, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs. 2010;2(4):428–439.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109.
   PubMed Web of Science ®Google Scholar
• Hyams J, Griffiths A, Veereman-Wauters G, et al. A multicenter open-label study assessing pharmacokinetics, efficacy, and safety of subcutaneous golimumab in pediatric subjects with moderately-severely active ulcerative colitis. Inflamm Bowel Dis. 2016;22(Suppl 1):S39.
   Google Scholar
• Quince C, Ijaz UZ, Loman N, et al. Extensive modulation of the fecal metagenome in children with Crohn’s disease during exclusive enteral nutrition. Am J Gastroenterol. 2015;110(12):1718–1729.
   PubMed Web of Science ®Google Scholar
• Kunde S, Pham A, Bonczyk S, et al. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013;56(6):597–601.
   PubMed Web of Science ®Google Scholar
• Suskind DL, Singh N, Nielson H, et al. Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2015;60(1):27–29.
   PubMed Web of Science ®Google Scholar
• Kellermayer R, Nagy-Szakal D, Harris RA, et al. Clinical, epigenetic, and metagenomic responses to serial fecal microbiome transplants in pediatric ulcerative colitis. Gastroenterology. 2014;146(5):S780.
   Web of Science ®Google Scholar
• Goyal A, Kufen A, Jackson Z, et al. A study of fecal microbiota transplantation in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(Suppl 1):S74.
   Google Scholar
• Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149(1):102–109.
   PubMed Web of Science ®Google Scholar
• Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149(1):110–118.
   PubMed Web of Science ®Google Scholar